Skip to main content

Search
Profile

Irwin D. Bernstein, MD

|
Irwin D. Bernstein, MD

Hematology-Oncology

On staff since July 1973

Children's Title: Chief, Division of Hematology/Oncology/Bone Marrow Transplantation; Director, Research Center for Childhood Cancer

Research Center: Ben Towne Center for Childhood Cancer Research

Overview

Board Certification(s)
Pediatrics
Pediatric Hematology-Oncology
Medical/Professional School
New York University School of Medicine, New York
Research Focus Area

Cancer

Publications

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Blood , 2010 Mar 25: 2372-9
Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells.
Cell stem cell , 2010 Mar 5: 251-64
Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution.
Nature medicine , 2010 Feb: 232-6
Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit.
Blood , 2010 Jan 28: 757-65
Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity.
Cell stem cell , 2008 Dec 4: 611-24
E47 controls the developmental integrity and cell cycle quiescence of multipotential hematopoietic progenitors.
Journal of immunology (Baltimore, Md. : 1950) , 2008 Nov 1: 5885-94
Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo.
Genes & development , 2008 Jun 15: 1677-89
Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival.
Blood , 2008 Apr 15: 4338-47
Notch target Hes5 ensures appropriate Notch induced T- versus B-cell choices in the thymus.
Blood , 2008 Mar 1: 2615-20
Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor.
Traffic (Copenhagen, Denmark) , 2008 Feb: 267-79
Clinical strategies to enhance posttransplant immune reconstitution.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , 2008 Jan: 94-9
ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2.
Journal of leukocyte biology , 2008 Jan: 200-11
The interaction of the Wnt and Notch pathways modulates natural killer versus T cell differentiation.
Stem cells (Dayton, Ohio) , 2007 Oct: 2488-97
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
Blood , 2007 May 15: 4168-70
Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1.
Blood , 2007 Apr 15: 3579-87
FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
Blood , 2006 Oct 15: 2764-9
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.
Blood , 2006 Mar 1: 2184-91
Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia.
Genes, chromosomes & cancer , 2005 Nov: 279-91
Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells.
Blood , 2005 Oct 15: 2693-9
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Cancer , 2005 Oct 1: 1442-52
Density of the Notch ligand Delta1 determines generation of B and T cell precursors from hematopoietic stem cells.
The Journal of experimental medicine , 2005 May 2: 1361-6
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
Blood , 2005 Feb 1: 1295-302
The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas.
Cancer research , 2004 Nov 1: 7794-800
The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin.
Blood , 2004 Jun 1: 4276-84
Establishment of a pluripotent preleukaemic stem cell line by expression of the AML1-ETO fusion protein in Notch1-immortalized HSCN1cl10 cells.
British journal of haematology , 2004 May: 353-7
Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia.
British journal of haematology , 2003 Nov: 431-5
Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates.
Bioconjugate chemistry , 2003 Sep-Oct: 927-33
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia.
Blood , 2003 Aug 15: 1474-9
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
Blood , 2003 Aug 15: 1466-73
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Blood , 2003 May 1: 3398-406
Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability.
Blood , 2003 Mar 1: 1784-9
Delta-1 enhances marrow and thymus repopulating ability of human CD34(+)CD38(-) cord blood cells.
The Journal of clinical investigation , 2002 Oct: 1165-74
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.
Blood , 2002 May 1: 3158-62
CD33 as a target for selective ablation of acute myeloid leukemia.
Clinical lymphoma , 2002 Mar: S9-11
Antibody-directed therapies for hematological malignancies.
Trends in molecular medicine , 2002 Feb: 69-76

Primary Office

Fred Hutchinson Cancer Research Center
FHCRC Box 358080 - MS D2-373
PO Box 19024
Seattle, WA 98109-1024
206-667-1212

Additional Offices

Seattle Children's
MB.8.501 - Hematology-Oncology
4800 Sand Point Way NE
Seattle, WA 98105
206-987-2106

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options